Factor Therapeutics Ltd - FTT share price

About

Factor Therapeutics Limited, formerly Tissue Therapies Limited, is a biotechnology company. The Company's principal activities include the development and commercialization of its intellectual property in wound care. The Company's lead program, VF-001, is a biologic product for wound care. VF-001 can be used in conjunction with standard care compression bandaging in the community setting. VF-001 is a fusion protein between a truncated vitronectin peptide and Insulin-like growth factor 1(IGF-1). The initial indication for VF-001 is for Venous Leg Ulcers (VLUs). The Company also has other programs in early development to address other wound applications, as well as new products in the ocular wound care space. Its pipeline includes VF-002, a viscous product to assess burn potential, particularly mucosal burns from radiation therapy, and VF-003 and VF-004, for growth in eye procedures/use of glaucoma stents, reduction of fibrosis and minimization of negative effects of ocular surgery.